GoAI
Get started
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc.

PLX

AMEXHealthcareBiotechnology

Open in GoAI

Latest quote

$2.37

$0.00 · 0.00%

Aug 21, 3:55 PM ET

PLX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

81

Deep Value

Momentum

57

Neutral

Sentiment

62

Bullish

Risk resilience

59

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Dror Bashan
Listed since
May 15, 1998
Employees
226

Market position

Volume
600.18K
0.84× average
Average volume
715.59K
Average daily volume
Market cap
191.76M USD
Beta
0.01
Market reference 1

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends79%24%-31%-86%Gross margin, FY2021: 57.37%Gross margin, FY2022: 58.87%Gross margin, FY2023: 64.91%Gross margin, FY2024: 54.46%Gross margin, FY2025: 47.85%Operating margin, FY2021: -53.36%Operating margin, FY2022: -27.32%Operating margin, FY2023: 15.97%Operating margin, FY2024: 7.34%Operating margin, FY2025: -10.43%Net margin, FY2021: -71.92%Net margin, FY2022: -31.33%Net margin, FY2023: 12.69%Net margin, FY2024: 5.49%Net margin, FY2025: -12.52%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 57.37%. Gross margin FY2022 58.87%. Gross margin FY2023 64.91%. Gross margin FY2024 54.46%. Gross margin FY2025 47.85%. Operating margin FY2021 -53.36%. Operating margin FY2022 -27.32%. Operating margin FY2023 15.97%. Operating margin FY2024 7.34%. Operating margin FY2025 -10.43%. Net margin FY2021 -71.92%. Net margin FY2022 -31.33%. Net margin FY2023 12.69%. Net margin FY2024 5.49%. Net margin FY2025 -12.52%.

Income trends

Revenue

52.74M USD-1.23%

Operating income

−5.5M USD−9.42M USD

Net income

−6.6M USD−9.54M USD
Income trends across reported periods74.8M USD37.57M USD340.8K USD−36.89M USDRevenue, FY2021: 38.35M USDRevenue, FY2022: 47.64M USDRevenue, FY2023: 65.49M USDRevenue, FY2024: 53.4M USDRevenue, FY2025: 52.74M USDOperating income, FY2021: −20.46M USDOperating income, FY2022: −13.01M USDOperating income, FY2023: 10.46M USDOperating income, FY2024: 3.92M USDOperating income, FY2025: −5.5M USDNet income, FY2021: −27.58M USDNet income, FY2022: −14.93M USDNet income, FY2023: 8.31M USDNet income, FY2024: 2.93M USDNet income, FY2025: −6.6M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 38.35M USD. Revenue FY2022 47.64M USD. Revenue FY2023 65.49M USD. Revenue FY2024 53.4M USD. Revenue FY2025 52.74M USD. Operating income FY2021 −20.46M USD. Operating income FY2022 −13.01M USD. Operating income FY2023 10.46M USD. Operating income FY2024 3.92M USD. Operating income FY2025 −5.5M USD. Net income FY2021 −27.58M USD. Net income FY2022 −14.93M USD. Net income FY2023 8.31M USD. Net income FY2024 2.93M USD. Net income FY2025 −6.6M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue52.74M USD53.4M USD65.49M USD47.64M USD38.35M USD
Cost of goods sold27.51M USD24.32M USD22.98M USD19.59M USD16.35M USD
Gross profit25.24M USD29.08M USD42.51M USD28.05M USD22M USD
Research and development19.05M USD12.97M USD17.09M USD29.35M USD29.73M USD
Selling, general, and administrative11.68M USD12.19M USD14.96M USD11.71M USD12.73M USD
Operating expenses30.74M USD25.16M USD32.05M USD41.06M USD42.46M USD
Interest income1.08M USD1.3M USD1.29M USD1.15M USD401K USD
Interest expense1.19M USD1.06M USD3.18M USD2.53M USD7.52M USD
Depreciation and amortization1.47M USD1.3M USD1.19M USD1.09M USD1.12M USD
Operating income−5.5M USD3.92M USD10.46M USD−13.01M USD−20.46M USD
Net income−6.6M USD2.93M USD8.31M USD−14.93M USD−27.58M USD

Company facts updated Aug 24, 2026.

PLX peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

—

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

—

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

—

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

—

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

—

Armata Pharmaceuticals, Inc. logo

ARMP

Armata Pharmaceuticals, Inc.

$5.10

—

ETFs holding PLX

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
4.53M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96—
Schwab International Small-Cap Equity ETF logoSchwab International Small-Cap Equity ETFSCHC
Market value
2.79M
Weight
0.05%
AUM
5.73B USD
Expense ratio
0.06%
Price / 1D
$51.25—
State Street SPDR Portfolio Developed World ex-US ETF logoState Street SPDR Portfolio Developed World ex-US ETFSPDW
Market value
2.11M
Weight
0.01%
AUM
41.92B USD
Expense ratio
0.03%
Price / 1D
$52.02—
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.66M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37—
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
985.13K
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25—
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
615.43K
Weight
0.04%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39—
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
514.04K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02—
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
218.85K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95—

Continue in GoAI

Research PLX

research.disclaimer